Coronavirus Update: Moderna Still Confident Of November Readout
Neck And Neck With Pfizer
The company said its own calculations suggested a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
You may also be interested in...
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
Board directors appointed at Athersys, Trillium Therapeutics and Viatris